Kelley Kiningham
Associate Dean for Student Affairs and Professor
College of Pharmacy & Health Sciences
PhD (Toxicology) University of Kentucky; MSc (Chemistry) Middle Tennessee State University; B.S. (Chemistry/Biology) Middle Tennessee State University
Location: McWhorter Hall 224
615-460-8128kelley.kiningham@belmont.edu
Biography
Dr. Kiningham joined the faculty at Belmont University College of Pharmacy in 2009 after having trained in the Graduate Center for Toxicology at the University of Kentucky. Following her graduate work which concentrated on the role of endogenous antioxidants in the neurodegenerative disease amyotrophic lateral sclerosis, she trained as a postdoctoral fellow in the field of oxidative stress and cancer.
Prior to joining the faculty at Belmont, Dr. Kiningham worked as a research scientist and academician in the Department of Pharmacology, Physiology and Toxicology at Marshall University where she received funding from the National Institutes of Health to further her research interests. In Dr. Kiningham’s laboratory several separate, but related areas of research are in progress including:
- Mechanisms of retinoid-mediated chemoresistance in neuroblastoma
- Modulation of redox status in neuronal cells undergoing differentiation therapy
- Neuroprotective approaches against methamphetamine dependent neuronal injury
Throughout her career she has published numerous peer reviewed articles and served on the Leadership and Professional Development committee in the Society for Free Radicals in Biology and Medicine. Currently she is a member of the Substance Abuse and Curricular Development Special Interest Groups in the American Association of Colleges of Pharmacy.
Dr. Kiningham’s teaching responsibilities at Belmont University College of Pharmacy are currently in the Pharmacodynamic series as well as Biochemistry and Immunology. She has curricular interests in course development, interdisciplinary education, classroom assessment and active learning modules.
View Dr. Kiningham's Curriculum Vitae
View Dr. Kiningham's areas of expertise and research interests
Scholarship of Teaching & Learning
Drug Abuse & Addiction
Society of Free Radical Biology & Medicine
National Association of Student Personnel Administration
2023 MEDGala Spotlight Award
2020 Staff Member of the Year
2019 Distinguished Mentor Award
2018 Distinguished Mentor Award
2018 Friend of the BSPA Chapter Award
2013 Rho Chi
2013 Most Influential Faculty Member, Class of 2013 Hooding Ceremony, Belmont University
2013 Presidential Faculty Achievement Award Recipient
2012 Presidential Faculty Achievement Award Finalist
2011 Health Information Technology Scholar
Silvis, A.M., McCormick, M., Spitz, D.R. and Kiningham, K.K. Redox balance influences differentiation status of neuroblastoma in the presence of all-trans retinoic acid. Redox Biology, 2016, (7) 88-96.
Clauson, A., Hahn, L., Frame, T., Hagan, A., Bynum, Leigh Ann, Thompson, M.E., Kiningham, K. An innovative escape exercise to assess student capability to work in teams and think critically. Currents in Pharmacy Teaching and Learning, 2019.
Karst, A., Boils, Caussandra and Kiningham, K.K. Antiproliferative and Chemosensitizing Effects of Metformin in Neuroblastoma Cell Lines. ASHP Midyear Meeting, Las Vegas, NV 2016.
Ham, A.J.L., Kiningham, K. and Clauson, A. ToxiClue Murder Mystery Game to Enhance Pharmacy Student Learning in a Toxicology Course. AACP Annual Meeting, Grapevine Texas, 2022.
Manganese Superoxide Dismutase Mediated Retinoid Differentiation of Neuroblastoma Research Challenge Grant Source: State of West Virginia/Marshall University.
$20,000; 2/1/03-1/31/04
Type of Award: Internal Pilot Project Grant
Mechanism of Thimerosal-Induced Neurotoxicity (1R15ES012209-01); Type of Award: Academic Research Enhancement Award (R15)$100,000
Funding: 4/1/03-4/1/06
Nutritional Intervention Model of Nitric Oxide for Cardioprotection with Chemotherapeutic Drugs, $20,000 Awarded 12/04-12/06
Type of Award: Research Challenge Award, West Virginia
Retinoids, NFB, and Manganese Superoxide Dismutase (MnSOD) in Neuroblastoma. $680,157; 7/1/04-6/30/09
Type of Award: Centers of Biomedical Research Excellence (COBRE)